Profound Medical (PROF) Financials

Profound Medical Corp (PROF) is a medical technology company that focuses on the development and commercialization of innovative therapies for the treatment of prostate cancer. The company's main product, TULSA-PRO, is a minimally invasive procedure that combines MRI and ultrasound to deliver precise and targeted thermal ablation to the prostate gland. This technology has the potential to revolutionize the way prostate cancer is treated by providing a non-invasive alternative to surgery or radiation. Profound Medical Corp was founded in 2008 and is headquartered in Mississauga, Canada.

The income statement of Profound Medical Corp (PROF) provides a snapshot of the company's financial performance over a specific period. It shows the company's total revenue, gross profit, operating expenses, and net income. For the latest fiscal year, Profound Medical Corp reported a total revenue of $12.5 million, a gross profit of $7.2 million, and an operating loss of $8.6 million. The company's net loss attributable to stockholders was $9.2 million. These figures demonstrate the company's ongoing investment in research and development as it continues to advance its innovative therapies for prostate cancer treatment.